Mark Pulido, chairman of the board of Quidel, said: “I speak for the full board of directors of Quidel in recognizing Caren Mason for the outstanding leadership and results she has delivered for Quidel.
“In her time with Quidel, she has generated double digit organic revenue growth, expanded operating margins from 2% to 24%, built a strong balance sheet with over $62 million of cash and secured a $120 million credit facility for expansion. She will be leaving Quidel with strong distributor partnerships, acute care and retail market expansion and new products and technologies in development.”
Ms Mason said: “I am honored to have had the opportunity to lead Quidel for over four years. Quidel is very well positioned for the future and the board is focusing upon very talented individuals with highly recognized and successful track records in diagnostics. I am confident that the board’s succession plan will be enthusiastically received by employees and investors.”